Randomized, multicentre, 2-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody Removab (anti-EpCAM x Anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Catumaxomab (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 14 Nov 2006 Status change
- 29 Oct 2005 New trial record.